

Laurent ARNAUD, MD, PhD.

Professor of Rheumatology

Nationality: [REDACTED]

Professional address: [REDACTED]
[REDACTED]

Mobile: [REDACTED]

Email: [REDACTED]

Twitter: @Lupusreference

ACADEMIC APPOINTMENTS:

- **Sept 2016 - ... : Full professor of Rheumatology**
 - French National Reference Center for Rare Auto-Immune Diseases, department of rheumatology (Pr Sibia), Strasbourg University Hospital, France.
 - Université de Strasbourg, Strasbourg, France.
- **July 2014 – Nov 2015: Associate Professor of Medicine (Habilitation à diriger la recherche)**
 - Hôpital Pitié-Salpêtrière, Paris, France and Université Pierre et Marie Curie, Paris, France.
- **Nov 2012 – July 2014: Assistant Professor of Medicine**
 - French National Reference Center for Systemic lupus, Hôpital Pitié-Salpêtrière, Paris, France and Université Pierre et Marie Curie, Paris, France.

MEDICAL TRAINING:

- Nov 2012 - Nov 2015: Fellowship in Internal Medicine and Rheumatology (clinical immunology)
 - French national reference Center for Systemic Lupus Erythematosus
 - Faculté de médecine Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France.
- 2003- Oct 2012: Medical Residency & MD degree
 - Assistance Publique – Hôpitaux de Paris, Paris, France.
- 1997-2003: Pre-graduate medical studies, Université Lyon I, Lyon, France.

RESEARCH TRAINING:

- **2016- ... : Team leader for epidemiological studies, National Reference Center for Rare Autoimmune disease, Strasbourg, France.**
- **2014 : Habilitation à Diriger la Recherche**
 - Université Pierre et Marie Curie, Paris, France.
- **2011-2014: Post-doctoral researcher**
 - Institut National de la Santé et de la recherche Médicale (INSERM), Paris, France.
- **2008 - 2011: PhD (Immunology)**
 - Université Pierre et Marie Curie, Paris, France.
 - Institut National de la Santé et de la Recherche Médicale (UMR 1135), Paris, France.
- 2007-2008: Master of Science (Immunology)

- Université Pierre et Marie Curie, Paris, France.
- Institut National de la Santé et de la Recherche Médicale (UMR 1135), Paris, France.

VISITING SCIENTIST:

- **Nov 2015 – Sept 2016: Invited SLE post-doctoral researcher**
 - CLIN-TRID (Pr van Vollenhoven), department of Rheumatology, Karolinska Institutet, Stockholm, Sweden.

Full member of the The Systemic Lupus Collaborating Clinics (SLICC group)

MAIN RESEARCH THEMES

- **Systemic Lupus Erythematosus**
- **Antiphospholipid syndrome**
- **Relapsing polychondritis**
- Autoimmune diseases
- Clinical & Epidemiological research
- Individualized therapeutic strategies

LAST FIVE YEARS MAIN PUBLICATIONS

1. Jolly M, Annapureddy N, **Arnaud L**, Devilliers H. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial. *Lupus*. 2019
2. Corneloup M, Maurier F, Wahl D, Muller G, Aumaitre O, Seve P, Blaison G, Pennaforte JL, Martin T, Magy-Bertrand N, Berthier S, **Arnaud L**, Bourredjem A, Amoura Z, Devilliers H. Disease-specific quality of life following a flare in systemic lupus erythematosus: an item response theory analysis of the French EQUAL cohort. *Rheumatology (Oxford)*. 2019 Oct 17
3. Parisi D, Bernier C, Chasset F, **Arnaud L**. Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: A systematic review and meta-analysis. *Autoimmun Rev*. 2019 Sep 11:102393.
4. Felten R, Scher F, Sagez F, Chasset F, **Arnaud L**. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. *Drug Des Devel Ther*. 2019 May 8;13:1535-1543.
5. Sebbag E, Felten R, Sagez F, Sibia J, Devilliers H, **Arnaud L**. The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of Diseases Database. *Ann Rheum Dis*. 2019 Apr 15. pii: annrheumdis-2019-215142.
6. Felten R, Scher F, Sibia J, Gottenberg JE, **Arnaud L**. The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials. *Autoimmun Rev*. 2019 Apr 6. pii: S1568-9972(19)30086-2
7. Chasset F, Richez C, Martin T, Belot A, Korganow AS, **Arnaud L**. Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers). *Joint Bone Spine*. 2019 Mar;86(2):165-171
8. **Arnaud L**, Mertz P, Gavand PE, Martin T, Chasset F, Tebacher-Alt M, Lambert A, Muller C, Sibia J, Lebrun-Vignes B, Salem JE. Drug-induced systemic lupus: revisiting the ever-changing

spectrum of the disease using the WHO pharmacovigilance database. *Ann Rheum Dis.* 2019 Feb 4.

9. Felten R, Sagez F, Gavand PE, Martin T, Korganow AS, Sordet C, Javier RM, Soulas-Sprauel P, Rivière M, Scher F, Poindron V, Guffroy A, **Arnaud L.** 10 most important contemporary challenges in the management of SLE. *Lupus Sci Med.* 2019 Jan 10;6(1):e000303.
10. **Arnaud L,** Mertz P, Gavand PE, Martin T, Chasset F, Tebacher M, Lambert A, Muller C, Sibia J, Lebrun-Vignes B, Salem JE. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the World Health Organization pharmacovigilance database. *ARD* 2019
11. Felten R, Sagez F, Gavand PE, Martin T, Korganow AS, Sordet C, Javier RM, Soulas-Sprauel P, Rivière M, Scher F, Poindron V, Guffroy A, **Arnaud L.** The 10 most important contemporary challenges in SLE. *Rheumatology (oxford)* 2019.
12. Grimaud F, Yelnik C, Pineton de Chambrun M, Amoura Z, **Arnaud L,** Costedoat Chalumeau N, Hachulla E, Lambert M, Roriz M, Sibia J, Papo T, Sacre K. Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study. *Rheumatology (Oxford).* 2019 Jan 3
13. **Arnaud L,** Gavand PE, Voll R, Schwarting A, Maurier F, Blaison G, Magy-Bertrand N, Pennaforte JL, Peter HH, Kieffer P, Bonnotte B, Poindron V, Fiehn C, Lorenz H, Amoura Z, Sibia J, Martin T. Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature. *Rheumatology (Oxford).* 2018 Dec 27. doi: 10.1093/rheumatology/key398.
14. Tamirou F, **Arnaud L** et al. Systemic lupus erythematosus: state of the art on clinical practice guidelines. *RMD Open.* 2018 Nov 27;4(2):e000793.
15. Mertz P, Belot A, Cervera R, Chuah TY, Dagna L, Damian L, Danda D, D'cruz D, Espinosa G, Frances C, Jayne D, Ooi KK, Kucharz EJ, Lebovics R, Marie I, Moulis G, Peng S, Sharma A, Suzuki N, Tanaka T, Van Vollenhoven R, Sibia J, Gottenberg JE, Chasset F, **Arnaud L.** The Relapsing Polychondritis Damage Index (RPDAM): development of a disease-specific damage score for relapsing polychondritis. *Joint Bone Spine.* 2018 Nov 15.
16. Rinagel M, Chatelus E, Jousse-Joulin S, Sibia J, Gottenberg JE, Chasset F, **Arnaud L.** Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature. *Autoimmun Rev.* 2018 Nov 5
17. Rednic S, Damian L, Talarico R, Scirè CA, Tobias A, Costedoat-Chalumeau N, Launay D, Mathian A, Matthews L, Ponte C, Toniati P, Bombardieri S, Frank C, Schneider M, Smith V, Cutolo M, Mosca M, **Arnaud L.** Relapsing polychondritis: state of the art on clinical practice guidelines. *RMD Open.* 2018 Oct 18;4(Suppl 1):e000788
18. Felten R, Dervovic E, Chasset F, Gottenberg JE, Sibia J, Scher F, **Arnaud L.** The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: A systematic review of trials. *Autoimmun Rev.* 2018 Jun 6
19. Belizna C, Stojanovitch L, Tervaert JWC, Fassot C, Henrion D, Loufrani L, Nagy G, Muchardt C, Hasan M, Ungeheuer MN, **Arnaud L.** Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities? *Autoimmun Rev.* 2018 Jun 6
20. Chasset F, **Arnaud L,** Francès C. Thromboprophylaxis and thalidomide in the non-cancer setting: toward an algorithm based on patient's history and underlying disease? *J Am Acad Dermatol.* 2018 May

21. **Arnaud L**, Lebrun-Vignes B, Salem JE. Checkpoint inhibitor-associated immune arthritis. *Ann Rheum Dis*. 2018 May
22. Moulis G, Pugnet G, Costedoat-Chalumeau N, Mathian A, Leroux G, Boutémy J, Espitia O, Bouillet L, Berthier S, Gaultier JB, Jeandel PY, Konaté A, Mékinan A, Solau-Gervais E, Terrier B, Wendling D, Andry F, Garnier C, Cathébras P, **Arnaud L**, Palmaro A, Cacoub P, Amoura Z, Piette JC, Arlet P, Lapeyre-Mestre M, Sailler L. Efficacy and safety of biologics in relapsing polycondritis: a French national multicentre study. *Ann Rheum Dis*. 2018 Mar 13 [Epub ahead of print]
23. Spielmann L, **Arnaud L**, Severac F, Messer L, Mahé A, Meyer A, Lannes B, Lipsker D, Sibilia J. Population-based prevalence of Eosinophilic (Shulman's) Fasciitis: a capture-recapture study. *Br J Dermatol*. 2018 Mar 11. doi: 10.1111/bjd.16535. [Epub ahead of print]
24. Cesbron E, Bessis D, Jachiet M, Lipsker D, Cordel N, Bouaziz JD, Bagot M, **Arnaud L**, Barbaud A, Francès C, Chasset F; Study Group of Systemic Diseases in Dermatology (EMSED: Étude des Maladies Systémiques en Dermatologie). Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: a multicenter-retrospective study. *J Am Acad Dermatol*. 2018 Feb 26. pii: S0190-9622(18)30334-7. doi: 10.1016/j.jaad.2018.02.049. [Epub ahead of print]
25. Danion F, Sparsa L, **Arnaud L**, Alsaleh G, Lefebvre F, Gies V, Martin T, Lukas C, Durckel J, Ardizzone M, Javier RM, Kleinmann JF, Moreau P, Blaison G, Goetz J, Chatelus E, Gottenberg JE, Sibilia J, Sordet C. Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhus: an open-label study of 15 patients. *RMD Open*. 2017
26. Chasset F, **Arnaud L**. Targeting interferons and their pathways in systemic lupus erythematosus. *Autoimmun Rev*. 2017
27. Chasset F, **Arnaud L**, Jachiet M, Monfort JB, Bouaziz JD, Cordoliani F, Bagot M, Barbaud A, Francès C. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. *J Am Acad Dermatol*. 2017
28. Chasset F, Tounsi T, Cesbron E, Barbaud A, Francès C, **Arnaud L**. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis. *J Am Acad Dermatol*. 2017
29. **Arnaud L**, Conti F, Chasset F, Massaro L, Denas G, Chasset F, Pengo V. Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's. *Autoimmun Rev*. 2017 Sep
30. Platten M, Kisten Y, Kälvesten J, **Arnaud L**, Forslind K, van Vollenhoven R. Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA. *RMD Open*. 2017 Jun 29;3(1).
31. Emamikia S, Gentline C, Chatzidionysiou K, **Arnaud L**, van Vollenhoven R. Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial. *Scand J Rheumatol*. 2017 Sep 1:1-10
32. Lebrun D, Mestrallet S, Dehoux M, Golmard JL, Granger B, Georgin-Lavialle S, **Arnaud L**, Grateau G, Pouchot J, Fautrel B. Validation of the Fautrel classification criteria for adult-onset Still's disease. *Semin Arthritis Rheum*. 2017
33. Le Besnerais M, **Arnaud L**, Boutémy J, Bienvenu B, Lévesque H, Amoura Z, Marie I. Aortic involvement in relapsing polycondritis. *Joint Bone Spine*. 2017

34. Gavand PE, Serio I, **Arnaud L**, Costedoat-Chalumeau N, Carvelli J, Dossier A, Hirschberger O, Mouthon L, Le Guern V, Korganow AS et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. *Autoimmun Rev.* 2017 May
35. Meyer A, Lannes B, Goetz J, Echaniz-Laguna A, Lipsker D, **Arnaud L**, Martin T, Gottenberg JE, Geny B, Sibilia J. Inflammatory myopathies: A new landscape. *Joint Bone Spine.* 2017
36. Rivière E, **Arnaud L**, Ebbo M, Allanore Y, Claudepierre P, Dernis E, Ziza JM, Miceli-Richard C, et al. Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases. *J Rheumatol.* 2017 Apr 15
37. **Arnaud L**, Nordin A, Lundholm H, Svenungsson E, Hellbacher E, Wikner J, Zickert A, Gunnarsson I. Effect of corticosteroids and cyclophosphamide on sex hormone profiles in male patients with Systemic Lupus Erythematosus and Systemic Sclerosis. *Arthritis Rheumatol.* 2017
38. Chasset F, Bouaziz JD, Costedoat-Chalumeau N, Francès C, **Arnaud L**. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. *Br J Dermatol.* 2017
39. Parodis I, Ding H, Zickert A, **Arnaud L**, Larsson A, Svenungsson E, Mohan C, Gunnarsson I. Serum soluble tumour necrosis factor receptor-2 (sTNFR₂) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. *Scand J Rheumatol.* 2016
40. van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, **Arnaud L**. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Ann Rheum Dis.* 2016 Nov 24
41. Guffroy A, Dervieux B, Gravier S, Martinez C, Deibener-Kaminsky J, Hachulla E, Michel M, Weber JC, Korganow AS, Arnaud L, Gottenberg JE, Sibilia J; Club des Rhumatismes et Inflammations (CRI). Systemic capillary leak syndrome and autoimmune diseases: A case series. *Semin Arthritis Rheum.* 2016 Aug 12
42. Legendre M, Devilliers H, Perard L, Groh M, Nefti H, Dussol B, Trad S, Touré F, Abad S, Boffa JJ, Frimat L, Torner S, Seidowsky A, Massy ZA, Saadoun D, Rieu V, Schoindre Y, Heron E, Frouget T, Lionet A, Glowacki F, **Arnaud L**, Mousson C, Besancenot JF, Rebibou JM, Bielefeld P. Clinicopathologic characteristics, treatment, and outcomes of tubulointerstitial nephritis and uveitis syndrome in adults: A national retrospective stroke-compliant study. *Medicine* 2016
43. Parodis I, **Arnaud L**, Gerhardsson J, Zickert A, Sundelin B, Malmström V, Svenungsson E, Gunnarsson I. Antiphospholipid Antibodies in Lupus Nephritis. *PLoS One.* 2016
44. Reygaerts T, **Arnaud L**, Devilliers H. Tobacco exposure in systemic lupus erythematosus: survival analysis should be preferred to a count of events. *Arthritis Rheum.* 2016
45. Chasset F, **Arnaud L**, Costedoat-Chalumeau N, Frances C. Increasing the dose of hydroxychloroquine for patients with refractory cutaneous lupus erythematosus: an open-label prospective pilot study. *J Am Acad Dermatol* 2016.

46. Dorgham K, Amoura Z, Parizot C, **Arnaud L**, Frances C, Pionneau C, Devilliers H, Pinto S, Zoorob R, Miyara M, Larsen M, Yssel H, Gorochov G, Mathian A. Ultraviolet light converts propranolol, a nonselective β -blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. *Eur J Immunol.* 2015 Sep
47. Chasset F, France C, Barete S, Amoura Z, **Arnaud L**. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. *J Am Acad Dermatol* 2015.
48. Duron L, Delestre F, Amoura Z, **Arnaud L**. Idiopathic and secondary capillary leak syndromes. *Rev Med Interne* 2015.
49. **Arnaud L**, Mathian A, Devilliers H, Ruffatti A, Tektonidou M, Forastiero R, Pengo V, Lambert M, Lefevre G, Martinez-Zamora M.A, Balasch J, Wahl D, Amoura Z. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. *Autoimmun Rev.* 2014 Oct.
50. **Arnaud L**, Mathian A, Devilliers H, Ruffatti A, Tektonidou M, Forastiero R, *et al.* Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. *Autoimmun Rev* 2014.
51. **Arnaud L**, Mathian A, Adoue D, Bader-Meunier B, Baudouin V, Belizna C, *et al.* Dépistage et prise en charge du risque cardiovasculaire au cours du lupus systémique : élaboration de recommandations pour la pratique clinique, à partir d'une analyse de la littérature et de l'avis d'experts. *Rev Med Interne* 2014.
52. Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Tolédano D, *et al.* Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease. *J Clin Oncol* 2014.
53. Devilliers H, Amoura Z, Besancenot JF, Bonnotte B, Pasquali JL, Wahl D, *et al.* Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. *Rheumatology (Oxford)* 2014.
54. **Arnaud L**, Mathian A, Bruckert E, Amoura Z. Le risque cardiovasculaire au cours du lupus systémique. *Rev Med Interne* 2014;35:723-9.
55. **Arnaud L**, Fagot JP, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study. *Autoimmun Rev* 2014;13:1082-1089.
56. Serio I, **Arnaud L**, Mathian A, Hausfater P, Amoura Z. Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. *Clin Rheumatol* 2014;33:1209-15.
57. Hervier B, Haroche J, **Arnaud L**, Charlotte F, Donadieu J, Néel A, *et al.* Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. *Blood* 2014;124:1119-26.
58. Haroche J, Cohen-Aubart F, **Arnaud L**, Hervier B, Charlotte F, Drier A, *et al.* Maladie d'Erdheim-Chester. *Rev Med Interne* 2014;35:715-22.
59. Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, *et al.* Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. *Blood* 2014;124:483-92.
60. Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, *et al.* Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. *Medicine (Baltimore)* 2014;93:150-7.

61. Zard E, **Arnaud L**, Mathian A, Chakhtoura Z, Hie M, Touraine P, *et al.* Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. *Autoimmun Rev* 2014;13:730-5.
62. **Arnaud L**, Devilliers H, Amoura Z. Survival analysis versus event count. *Ann Rheum Dis* 2014;73:e37.
63. Hommel B, Charuel JL, Jaureguiberry S, **Arnaud L**, Courtin R, Kassab P, *et al.* Chronic malaria revealed by a new fluorescence pattern on the antinuclear autoantibodies test. *PLoS One* 2014;9:e88548.
64. Haroche J, **Arnaud L**, Cohen-Aubart F, Hervier B, Charlotte F, Emile JF, *et al.* Erdheim-Chester disease. *Curr Rheumatol Rep* 2014;16:412.
65. Mathian A, **Arnaud L**, Amoura Z. Physiopathologie du lupus systémique : le point en 2014. *Rev Med Interne* 2014;35:503-11.
66. **Arnaud L**, Mathian A, Ruffatti A, Erkan D, Tektonidou M, Cervera R, *et al.* Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. *Autoimmun Rev* 2014;13:281-91.
67. **Arnaud L**, Mathian A, Haroche J, Gorochov G, Amoura Z. Pathogenesis of relapsing polyarthritides: a 2013 update. *Autoimmun Rev* 2014;13:90-5.
68. Tedeschi B, **Arnaud L**, Hie M, Mathian A, Amoura Z. Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen. *Ann Rheum Dis* 2014;73:474-5.
69. Goëb V, Ardizzone M, **Arnaud L**, Avouac J, Baillet A, Belot A, *et al.* Recommendations for using TNF α antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health. *Joint Bone Spine* 2013;80:574-81.
70. Janssens P, **Arnaud L**, Galicier L, Mathian A, Hie M, Sene D, *et al.* Lupus enteritis: from clinical findings to therapeutic management. *Orphanet J Rare Dis* 2013;8:67.
71. Haroche J, **Arnaud L**, Cohen-Aubart F, Hervier B, Charlotte F, Emile JF, *et al.* Erdheim-Chester disease. *Rheum Dis Clin North Am* 2013;39:299-311.
72. Haroche J, Cohen-Aubart F, Emile JF, **Arnaud L**, Maksud P, Charlotte F, *et al.* Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. *Blood* 2013;121:1495-500.

INTERNATIONAL & NATIONAL INVITED SEMINARS (academic only, not pharma):

- "Biologics in SLE, where do we stand in 2019" : session plénière de du congrès de la Belgium Society for Internal Medicine, Bruxelles (La Hulpe), décembre 2019
- "Challenges in SLE", University of Ghent, Belgique, Novembre 2019
- "Environmental factors in auto-immune diseases: myth or fact?", 4th International Academy of Auto-immunity, October 11-13, 2019 - Saint Petersburg, Russia
- "From interferons to lupus", département de Rhumatologie de Fribourg (Pr Dudler), Suisse, 2019
- "Drug-induced SLE", 9th EULAR Scientifically Endorsed Course on Systemic Lupus Erythematosus, Pisa mars 2019
- "Practical management of the antiphospholipid syndrome", Congreso Panamericano de Reumatología 2019 (PANLAR), Quito (Equateur), 2019.
- "What's hot in SLE in 2019?", Congreso Panamericano de Reumatología 2019 (PANLAR), Quito (Equateur), set in 2019.

- "Antiphospholipid syndrome: what do we need to know?", Congreso Panamericano de Reumatología 2019 (PANLAR), Quito (Equateur), set in 2019.
- "Relapsing polychondritis: what is new in 2018?", congrès National de la Société Italienne de Rhumatologie, Rimini (Italie), 2018
- "What's new about SLE in 2018?", Annual Meeting of the Argentinian Society of Rheumatology, Mendoza (Argentine), 2018.
- "Antiphospholipid syndrome: an update", Annual Meeting of the Argentinian Society of Rheumatology, Mendoza (Argentine), 2018.
- "Interferonopathies: from lupus to lupus", Porto Auto-Immune Meeting, Porto, Portugal, 2018
- "From autoimmunity to autoinflammatory diseases", Porto Auto-Immune Meeting, Porto, Portugal, 2018
- "Can we prevent the antiphospholipid syndrome", Rheuma-dialog, Université de Düsseldorf Juillet 2018, Allemagne.
- "Corticosteroids, friends or foes?", Rheuma-summer school, Lisbon, 2018.
- "Treatment targeting Interferons and their pathways in SLE", Autoimmunity Congress, Lisbon, 2018
- "Smoking and SLE: a strong impact on disease prevalence, activity, damage and response to treatment", European Lupus Congress, Düsseldorf, Mars 2018.
- "Recommendations in Relapsing polychondritis: where do we stand", Meeting ERN ReCONNECT, Pisa, Italie, Février 2018.
- "IL-17 : de la cytokine au traitement ciblé", Journée National de Rhumatologie Tunisienne, Sfax, Tunisie, Janvier 2018
- Porto autoimmune Meeting 2017, Porto, Portugal.
- "Is SLE a difficult-to-treat disease", European Rheumatology Summer School, Leipzig 2017
- Master Class "Treatment of thrombosis with VKA in APS", European Antiphospholipid Forum, Nancy, 2017.
- "Environmental factors in RA and Sjogren's", Bed-to-Benchside Immunology, Freiburg, Germany, 2017
- "Primary prevention of thrombosis in patients with aPL : where do we stand ?", European Antiphospholipid Forum, Nancy, 2017.
- "Primary prevention of thrombosis in patients with aPL", CORA Bologna, Italie, 2017.
- "Global Management of patients with systemic lupus", Stockholm, 2015.
- « Clarkson's disease and other capillary leak syndromes», Paris, 2015.
- "Global Management of patients with autoimmune diseases", Porto's Autoimmune Meeting III, Porto, Portugal, 2014.
- "Primary prevention of thrombosis in patients with aPL", Bondy, France, 2014.
- "Relapsing Polychondritis", Annual meeting of the Brest-Nantes-Rennes centers for autoimmune diseases, Nantes, France, 2014.
- "When to think about auto-immune diseases in the ICU" (DIU Réanimation des Malades Immunodéprimés), Paris, 2014.
- 9th meeting of European Forum on Antiphospholipid, Cracovie, Pologne, 2013.
- "Transcriptome de la maladie d'Edheim-Chester", ECD Medical Symposium, San Diego, USA, 2013.
- "Shall we prescribe aspirin in APS patients", Ten topics in Rheumatology, Beirut, Liban, 2013.

- "Clarkson's disease", XVIème journée d'immunopathologie clinique de la Pitié-Salpêtrière, Paris, 2013.
- "Relapsing polychondritis", Rencontres en Immunologie et Immunothérapie, Paris, 2013
- "Introduction to méta-analyse", Master 2 Recherche « Maîtrise de la Recherche », Reims, France, 2013.
- "Cardiovascular risk in SLE", 3rd National Meeting Day for SLE, Paris, 2013.
- "Aspirin & aPL", Department of internal Medecine of hôpital Bichat (Pr Papo), Paris, 2013.
- "Polychondritis", Department of Rheumatology of hôpital de la Pitié (Pr Fautrel), Paris, 2013.
- "Aspirin & aPL", Department of internal Medecine of hôpital Foch (Pr Blétry), Paris, 2013.
- "CNS involvement in SLE", Porto's Autoimmune Meeting II, Porto, Portugal, 2012.
- "Epidemiology of SLE", 2nd National Meeting Day for SLE, Paris, 2012.
- "Polychondritis", Department of Rheumatology of hôpital Bichat (Pr Meyer), Paris, 2012.
- "From polychondritis to Clarkson's disease", Department of Rheumatology of CHU de Strasbourg (Pr Sibilia), Strasbourg, France, 2012.
- "Clarkson's disease", Société de Réanimation de langue Française, Paris, 2012.
- "Use of MPA-AUC in SLE", 1st National Meeting Day for SLE, Paris, 2011.
- "Traitement des vascularites réfractaires", NEDAI XVII, Almancil, Portugal, 2011.
- "Cytokines & Erdheim-Chester Disease", French Histiocytoses study group, Paris, 2011.
- "Takayasu's arteritis", Department of Rheumatology of Kremlin-Bicêtre (Pr Mariette), Bicêtre, 2010.
- "Refractory SLE", Porto's Autoimmune Meeting (PAM-I), Porto, Portugal, 2010.
- "Takayasu's arteritis", XIVème journée d'immunopathologie clinique de la Pitié-Salpêtrière, Paris, 2010.
- "Pathogenesis of relapsing Polychondritis", 5^{ème} journée Jacques Courtin, Paris, 2010.
- "PET-scan & Takayasu", 43ème congrès du Collège Français de pathologie Vasculaire, Paris, 2009.

SELECTED FUNDED RESEARCH:

- 2012: Co-principal investigator of the study « Immunophenotypic analysis of circulating histiocytes in Erdheim-Chester disease » funded by ECD Global Alliance, **USA: 50 000\$.**
- 2011: Principal investigator of the study (AOM11237, "MYCADO" study) « Evaluation of individual patient adjustment of doses of mycophenolate mofetil in the induction of proliferative lupus nephritis » funded by the national French ministry (PHRC): **395 000 euros**
- 2010: Principal investigator of the study "Pathogenesis of relapsing polychondritis" funded by Région Île-De-France (Partenariat Institution Citoyens « PICRI »): **136 000 euros**
- 2009-2011: Principal investigator of the study "Pathogenesis of relapsing polychondritis" funded by Association Francophone Contre La Polychondrite (AFPCA): **155 000€.**
- 2009 : Co-principal investigator of the study « Transcriptome analysis of the monocytes in Erdheim-Chester disease » funded by ECD Global Alliance, USA: **50 000 dollars US.**
- 2008 : Principal investigator of the study "Pathogenesis of relapsing polychondritis" funded by Fonds d'Etudes et de Recherche du Corps Médical des hôpitaux de Paris: **23 000 euros**

- 2007 : Principal investigator of the study "Pathogenesis of Takayasu's arteritis" funded by Fondation Hippocrate-Servier: **15 000 euros**

TEACHING:

Faculty teaching:

- Undergraduate students
- Postgraduate students
- Residents
- Continuous professional development of health professionals

Teaching-related activities:

- Development and sharing of teaching innovations, materials and strategies
- Advising and mentoring of younger colleagues about teaching-related issues
- Organization of local, national and international seminars, workshops or conferences
- Contributions to the development of policies on teaching and learning
- Teaching-related publications

OTHER PROFESSIONAL ACTIVITIES:

- Member of the French Society of Internal Medicine (SNFMI).
- Member of the French Society of Rheumatology (SFR)
- Member of the SLICC group (Systemic Lupus International Collaborating Clinics)
- Member of the ERN ReCONNECT
- Member of the board of La Revue de Médecine Interne.
- Member of the board of Association Francophone contre la Polychondrite.
- Member of the abstract selection committee of the French Society of Internal Medicine (SNFMI).
- Referee for: Circulation, Blood, ARD, Arthritis & Rheumatology, Scand Journal Rheum, Rheumatology (Oxford), The journal of Rheumatology, Nephrology, Dialysis and Transplantation, Mayo Clinic proceedings, Atherosclerosis, thrombosis and vascular biology, Lupus, European Journal of internal medicine, Expert Opinion On Therapeutic Targets, Current Medicinal Chemistry, Respiration, La Presse Médicale, La Revue de Médecine Interne.

The 08th of January 2020

A handwritten signature in black ink, appearing to be 'A. A. A.', written in a cursive style.